CCHT is committed to growing into an open and
professional international enterprise.


Changchun High-tech Industry (Group) Co., Ltd. was established by Changchun High-tech Industry Development Corporation in June 1993, with a total share capital of 137,500,000 shares.

 

On December 18, 1996, CCHT stocks were listed at Shenzhen Stock Exchange. It is among the first batch of listed companies in northeast China.

 

Since its establishment more than 20 years ago, CCHT successfully transformed from high-tech area infrastructure construction into an enterprise group focusing on the field of medical science and technology innovation and implementing industrial investment. CCHT has adhered to the corporate culture of ‘‘innovation, concentration, generosity and sharing’’, practicing the core values of creating value for customers, creating opportunities for employees, creating benefits for shareholders and taking responsibility for the society. It has established its industrial orientation with biopharmaceutical industry as the primary and real estate industry as the supplement, has formed the development platform for three industries including genetic engineering pharmaceuticals, biological vaccines and modern traditional Chinese medicine, has realized the vigorous development pattern of ‘‘four carriages’’ including GeneScience Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘‘GenSci’’, Changchun BCHT Biotechnology Co., Ltd. (hereinafter referred to as ‘‘BCHT’’, Jilin Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as ‘‘Huakang Pharmaceutical’’) and Changchun High-tech Real Estate Development Co., Ltd. (hereinafter referred to as ‘‘High-tech Real Estate’’ and has opened up a good situation of shared development and win-win cooperation. CCHT ranked 73rd and 56th among the top 100 pharmaceutical industries in China in 2017 and 2018, respectively.

 

PIV5 vaccine platform project
Biao He, Chinese-American, is a distinguished tenured professor at the university of Georgia school of veterinary medicine, and an expert on the "thousand talents program" in China. The project is based on PIV5 carrier platform of proprietary intellectual property rights and the platform for a series of technologies for the preparation of Vero cell-based virus vaccine and 4 projects are derived accordingly
MORE
Oral growth hormone project
Rani is developing an oral preparation, sugar needle capsules (Rani pills), which can convert injectable drugs into pills for oral administration. CCHT invested $15 million to participate in the first round D financing of Rani. After taking a stake in Rani, CCHT will have the opportunity to cooperate in the development of new biological oral preparations (oral growth hormone, etc.) projects
MORE
Bispecific antibody project
Immunowake, Inc. founded by WU Xiaoyun, a senior expert in the field of antibody drugs, is biotechnology research and development company. Its core technology is BiART platform technology to develop bispecific antibody drugs. This technology differs from the existing global research & development ideas, has global intellectual property rights and solves the common problem of critical defects of bispecific antibody drugs under research
MORE